Komori
Management planning4592SanBio Company LimitedPharmaceuticals

Notice Regarding the Domestic Consolidation of the Akuugo® Production System Following the Closure of Minaris’s U.S. Plant

Following the closure of ミナリス's U.S. plant, the upstream manufacturing process for the アクーゴ® product will be transferred to 日本ミナリス's Yokohama Plant, integrating the domestic manufacturing system from upstream through downstream processes. In parallel, the company will diversify its manufacturing contractors, including JCR Pharmaceuticals.

Worth reading
8Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Items stated in the management plan

Publication date31 August 2026

This document does not state the plan name, plan period, or numerical targets.

Key initiatives
01Domestic integration of the manufacturing process
02Diversification of manufacturing contractors
Items stated in the management plan
ItemDetails
Key initiativesDomestic integration of the manufacturing process, Diversification of manufacturing contractors
Publication date31 August 2026
Items this document does not state (23)
Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The closure of ミナリス's U.S. plant will be carried out as part of the company's restructuring of its production system. The company explains that domestic integration will strengthen the consistency of manufacturing management, improve production stability and efficiency, and establish a production system capable of meeting future increases in demand.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Domestic Consolidation of the Akuugo® Production System Following the Closure of Minaris’s U.S. Plant | SanBio Company Limited (4592) timely disclosure | Komori